UROGYNECOLOGY: Edited by Kavita MishraPlatelet rich plasma for the management of urogynecological disorders: the current evidenceProdromidou, Anastasia; Grigoriadis, Themos; Athanasiou, Stavros Author Information Urogynecology Unit, 1st Department of Obstetrics and Gynaecology, Alexandra Hospital, Athens, Greece Correspondence to Stavros Athanasiou, MD, PhD, Prof, Urogynecology Unit, 1st Department of Obstetrics and Gynaecology, Alexandra Hospital, Athens 11528, Greece. Tel: +302132162588; e-mail: [email protected] Current Opinion in Obstetrics and Gynecology: December 2022 - Volume 34 - Issue 6 - p 396-401 doi: 10.1097/GCO.0000000000000820 Buy Metrics Abstract Purpose of review Our objective is to review the currently available literature on the use of platelet-rich plasma (PRP) in patients with pelvic floor disorders and to critically appraise the latest evidence on the safety and efficacy of the PRP application. Recent findings The evidence on the use of PRP for the treatment of stress urinary incontinence (SUI) appears promising, although limited to case series, case reports and animal studies. PRP has also been proposed to enhance the surgical outcomes of pelvic organ prolapse (POP) by native tissue repair with promising success rates. The application of PRP in other PFDs including vaginal fistulas, genitourinary syndrome of menopause (GSM), mesh exposure and lichen sclerosus has been also associated with beneficial outcomes and a favorable safety profile. Summary The currently available literature indicates that PRP could have a beneficial effect as a single or adjuvant treatment in patients with SUI, POP, GSM, vaginal fistula and genital lichen sclerosus with minimal adverse events. However, valid evidence is still lacking and further well-designed studies are warranted in the field to confirm the validity of the so far reported outcomes. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.